Burkitt's Lymphoma: Molecular Pathogenesis and Treatment

Publisher Website
Google Scholar
Abstract
Dennis Burkitt first described a unique form of sarcoma involving the jaw of African children in 1958 (1). Before long, Burkitt's lymphoma became an accepted distinct pathologic and clinical diagnosis, and over the ensuing 30 years, much has been learned about the molecular basis of this highly aggressive non-Hodgkin's lymphoma (NHL). This disease has been the subject of multiple successful scientific and clinical studies (2–6) and serves as a model of oncogenesis in malignant lymphomas. Indeed, the most exciting developments in the study of Burkitt's lymphoma come from research on the molecular pathogenesis of this highly aggressive albeit curable lymphoma. Clinically, the incremental and rational development of treatment regimens over the past 20 years has led to the cure of most patients with Burkitt's lymphomas (2–6). The success of these regimens, however, has not been achieved without significant toxicity, and further refinements are needed to reduce toxicity and to overcome drug resistance in the few incurable patients.

This publication has 59 references indexed in Scilit: